PageSourceSearch

https://www.lyfgeniahcp.com/

html lyfgeniahcp.com collected 2026-10-04 13:23:43 UTC 85,745 bytes, 1,963 lines download raw bytes

1<!doctype html><html><head>
2  <meta charset="utf-8">
3<meta name="viewport" content="width=device-width, initial-scale=1">
4
5
6
7<!-- Google Tag Manager -->
8<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
9new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
10j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
11'https://www.googletagmanager.com/gtm.js?id='+i+dl+'&gtm_auth=CkWWfkoT46nflVJbaj6qaA&gtm_preview=env-1&gtm_cookies_win=x';f.parentNode.insertBefore(j,f);
12})(window,document,'script','dataLayer','GTM-K37NR7BP');</script>
12
13
14<!-- Google Analytics 4 -->
vendor: 64 bytes, lines 14-15
14
15<script async src="https://www.googletagmanager.com/gtag/js?id=
15G-XJX8WRHVGB
vendor: 12 bytes, line 15
15"></script>
16<script>
17  
vendor: 133 bytes, lines 17-20
17window.dataLayer = window.dataLayer || [];
18  function gtag(){dataLayer.push(arguments);}
19  gtag('js', new Date());
20  gtag('config', '
20G-XJX8WRHVGB
vendor: 4 bytes, line 20
20');
21</script>
21
22
23<!-- Microsoft Clarity -->
24<script type="text/javascript">
25  (function(c,l,a,r,i,t,y){
26    c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)};
27    t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i;
28    y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y);
29  })(window, document, "clarity", "script", "k2vq0zw5pl");
30</script>
30
31
32<!-- Bing Ads UET -->
33<script>(function(w,d,t,r,u){var f,n,i;w[u]=w[u]||[],f=function(){var o={ti:"187245285"};o.q=w[u],w[u]=new UET(o),w[u].push("pageLoad")},n=d.createElement(t),n.src=r,n.async=1,n.onload=n.onreadystatechange=function(){var s=this.readyState;s&&s!=="loaded"&&s!=="complete"||(f(),n.onload=n.onreadystatechange=null)},i=d.getElementsByTagName(t)[0],i.parentNode.insertBefore(n,i)})(window,document,"script","//bat.bing.com/bat.js","uetq");</script>
33
34
35<!-- Snitcher radar -->
36<script async src="https://cdn.snitcher.com/releases/latest/radar.min.js"></script>
36
37
38<!-- ActiveCampaign Diffuser -->
39<script async src="https://diffuser-cdn.app-us1.com/diffuser/diffuser.js"></script>
39
40
41<!-- ActiveCampaign Prism + trackcmp (site tracking) -->
42<script>
43  (function(){
44    var prismId = '2f3baaa6-cfa3-408f-9933-3c5a6ba8e31a';
45    var trackId = '69651742';
46    var url = encodeURIComponent(window.location.href);
47    var s1 = document.createElement('script');
48    s1.async = true;
49    s1.src = 'https://prism.app-us1.com?a=' + trackId + '&u=' + url + '&t=' + prismId;
50    document.head.appendChild(s1);
51    var s2 = document.createElement('script');
52    s2.async = true;
53    s2.src = 'https://trackcmp.net/t_prism_sitemessages.php?trackid=' + trackId + '&prismid=' + prismId + '&url=' + url;
54    document.head.appendChild(s2);
55  })();
56</script>
56
57
58
59
60
61<title>LYFGENIA™ (lovotibeglogene autotemcel) Gene Therapy | Healthcare Professional website</title>
62<meta name="description" content="">
63
64<link rel="icon" type="image/svg+xml" href="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/favicon.svg">
65<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/[email protected]/dist/css/bootstrap.min.css">
66<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css" referrerpolicy="no-referrer">
67<link rel="preconnect" href="https://fonts.googleapis.com">
68<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
69<link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato:wght@400;700&amp;family=Nunito:wght@400;700&amp;display=swap">
70<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195482471/1788288955799/template_fonts.min.css">
71<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213194501275/1789500550860/template_vendor.min.css">
72<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195452419/1788288958324/template_layout.min.css">
73<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195482473/1788974063950/template_theme.min.css">
74<link rel="stylesheet" href="https://unpkg.com/tippy.js@6/dist/tippy.css">
75<link rel="stylesheet" href="https://unpkg.com/tippy.js@6/themes/light.css">
76<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195452428/1788288956772/template_page-subnav.min.js" defer></script>
76
77
78
79
80
81  
82
83<script>window.GTX_ENV = { API_URL: "https://gx-backend-prod.azurewebsites.net" };</script>
83
84
85<meta name="viewport" content="width=device-width, initial-scale=1">
86
87    
88    <meta property="og:description" content="">
89    <meta property="og:title" content="LYFGENIA™ (lovotibeglogene autotemcel) Gene Therapy | Healthcare Professional website">
90    <meta name="twitter:description" content="">
91    <meta name="twitter:title" content="LYFGENIA™ (lovotibeglogene autotemcel) Gene Therapy | Healthcare Professional website">
92
93    
94
95    
96    <style>
97a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px}
98</style>
99
100<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/214231167294/1790953900161/module_hcp-honesty-modal-global-module.min.css">
101<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213195482464/1790953899913/module_disclaimer-bar-global-module.min.css">
102<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213194501260/1790953900927/module_header-branding-global-module.min.css">
103<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213195452336/1790953900889/module_header-nav-global-module.min.css">
104<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/214825911471/1787845330681/module_signup-module.min.css">
105<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213195452343/1790953901243/module_isi-global-module.min.css">
106
107<style>
108  #hs_cos_wrapper_isi .banner-icon-expand i::before { background-image:url(https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_dtc_icon_carrot_up_down.svg); }
109
110#hs_cos_wrapper_isi .banner-icon-collapse i::before { background-image:url(https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_dtc_icon_carrot_up_down.svg); }
111
112</style>
113
114<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213194501257/1790953899670/module_cards-module.min.css">
115
116<style>
117  #hs_cos_wrapper_widget_1781762256264 .cards {
118  display:flex;
119  flex-direction:row;
120  flex-wrap:wrap;
121  gap:0px;
122  justify-content:flex-start;
123  align-items:stretch;
124  max-width:100%;
125  margin-left:auto;
126  margin-right:auto;
127}
128
129#hs_cos_wrapper_widget_1781762256264 .card-1 {
130  border:none;
131  border-radius:0;
132  flex-direction:column;
133  justify-content:flex-start;
134  align-items:flex-start;
135}
136
137#hs_cos_wrapper_widget_1781762256264 .card-1 .cards__icon {}
138
139#hs_cos_wrapper_widget_1781762256264 .card-1 .cards__title {}
140
141#hs_cos_wrapper_widget_1781762256264 .card-1 .cards__copy {}
142
143#hs_cos_wrapper_widget_1781762256264 .card-1 .cards__btn {}
144
145@media (max-width:767px) {
146  #hs_cos_wrapper_widget_1781762256264 .cards {
147    display:grid !important;
148    grid-template-columns:repeat(1,minmax(0,1fr));
149    gap:0px;
150    justify-items:stretch;
151    margin-left:auto;
152    margin-right:auto;
153    width:auto;
154  }
155
156  #hs_cos_wrapper_widget_1781762256264 .cards__card-link { width:100%; }
157
158  #hs_cos_wrapper_widget_1781762256264 .cards__icon:not(.icon-shadow-border) img {
159    width:auto;
160    height:auto;
161  }
162
163  #hs_cos_wrapper_widget_1781762256264 .cards__icon.icon-shadow-border img {
164    width:100%;
165    height:auto;
166  }
167
168  #hs_cos_wrapper_widget_1781762256264 .cards__card.purple-divider-side {
169    flex-direction:row;
170    align-items:flex-start;
171  }
172
173  #hs_cos_wrapper_widget_1781762256264 .card-1 { flex-direction:column; }
174
175  #hs_cos_wrapper_widget_1781762256264 .card-1 {}
176
177  #hs_cos_wrapper_widget_1781762256264 .card-1 .cards__icon {}
178
179  #hs_cos_wrapper_widget_1781762256264 .card-1 .cards__title {}
180
181  #hs_cos_wrapper_widget_1781762256264 .card-1 .cards__copy {}
182
183  #hs_cos_wrapper_widget_1781762256264 .card-1 .cards__btn {}
184}
185
186</style>
187
188<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/213192069936/1790953900218/module_footer-global-module.min.css">
189<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/214208692642/1787670526983/module_modal-module.min.css">
190<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/214210175022/1788968077674/module_hero-module.min.css">
191
192<style>#hs_cos_wrapper_widget_1780477538954 .hero-fullwidth {
193  position:relative;
194  width:100vw;
195  max-width:none;
196  left:50%;
197  right:50%;
198  margin-left:-50vw;
199  margin-right:-50vw;
200}
201
202@media (max-width:767px) {
203  #hs_cos_wrapper_widget_1780477538954 .lyf-homepage-hero { background-image:url(https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_image_Hero-M-2x.jpg) !important; }
204}
205</style>
206
207
208<style>
209  #hs_cos_wrapper_widget_1780482725784 .cards {
210  display:flex;
211  flex-direction:row;
212  flex-wrap:wrap;
213  gap:0px;
214  justify-content:flex-start;
215  align-items:stretch;
216  max-width:100%;
217  margin-left:auto;
218  margin-right:auto;
219}
220
221#hs_cos_wrapper_widget_1780482725784 .card-1 {
222  border:none;
223  border-radius:0;
224  flex-direction:column;
225  justify-content:flex-start;
226  align-items:flex-start;
227}
228
229#hs_cos_wrapper_widget_1780482725784 .card-1 .cards__icon {}
230
231#hs_cos_wrapper_widget_1780482725784 .card-1 .cards__title {}
232
233#hs_cos_wrapper_widget_1780482725784 .card-1 .cards__copy {}
234
235#hs_cos_wrapper_widget_1780482725784 .card-1 .cards__btn {}
236
237@media (max-width:767px) {
238  #hs_cos_wrapper_widget_1780482725784 .cards {
239    display:grid !important;
240    grid-template-columns:repeat(1,minmax(0,1fr));
241    gap:0px;
242    justify-items:stretch;
243    margin-left:auto;
244    margin-right:auto;
245    width:auto;
246  }
247
248  #hs_cos_wrapper_widget_1780482725784 .cards__card-link { width:100%; }
249
250  #hs_cos_wrapper_widget_1780482725784 .cards__icon:not(.icon-shadow-border) img {
251    width:auto;
252    height:auto;
253  }
254
255  #hs_cos_wrapper_widget_1780482725784 .cards__icon.icon-shadow-border img {
256    width:100%;
257    height:auto;
258  }
259
260  #hs_cos_wrapper_widget_1780482725784 .cards__card.purple-divider-side {
261    flex-direction:row;
262    align-items:flex-start;
263  }
264
265  #hs_cos_wrapper_widget_1780482725784 .card-1 { flex-direction:column; }
266
267  #hs_cos_wrapper_widget_1780482725784 .card-1 {}
268
269  #hs_cos_wrapper_widget_1780482725784 .card-1 .cards__icon {}
270
271  #hs_cos_wrapper_widget_1780482725784 .card-1 .cards__title {}
272
273  #hs_cos_wrapper_widget_1780482725784 .card-1 .cards__copy {}
274
275  #hs_cos_wrapper_widget_1780482725784 .card-1 .cards__btn {}
276}
277
278</style>
279
280
281<style>
282  #hs_cos_wrapper_widget_1781779179924 .cards {
283  display:flex;
284  flex-direction:row;
285  flex-wrap:wrap;
286  gap:24px;
287  justify-content:flex-start;
288  align-items:stretch;
289  max-width:100%;
290  margin-left:auto;
291  margin-right:auto;
292}
293
294#hs_cos_wrapper_widget_1781779179924 .card-1 {
295  width:49%;
296  border:none;
297  border-radius:0;
298  flex-direction:column;
299  justify-content:flex-start;
300  align-items:flex-start;
301}
302
303#hs_cos_wrapper_widget_1781779179924 .card-1 .cards__icon {}
304
305#hs_cos_wrapper_widget_1781779179924 .card-1 .cards__title {}
306
307#hs_cos_wrapper_widget_1781779179924 .card-1 .cards__copy {}
308
309#hs_cos_wrapper_widget_1781779179924 .card-1 .cards__btn {}
310
311#hs_cos_wrapper_widget_1781779179924 .card-2 {
312  width:48%;
313  border:none;
314  border-radius:0;
315  flex-direction:column;
316  justify-content:flex-start;
317  align-items:flex-start;
318}
319
320#hs_cos_wrapper_widget_1781779179924 .card-2 .cards__icon {}
321
322#hs_cos_wrapper_widget_1781779179924 .card-2 .cards__title {}
323
324#hs_cos_wrapper_widget_1781779179924 .card-2 .cards__copy {}
325
326#hs_cos_wrapper_widget_1781779179924 .card-2 .cards__btn {}
327
328@media (max-width:767px) {
329  #hs_cos_wrapper_widget_1781779179924 .cards {
330    display:grid !important;
331    grid-template-columns:repeat(1,minmax(0,1fr));
332    gap:24px;
333    justify-items:stretch;
334    margin-left:auto;
335    margin-right:auto;
336    width:auto;
337  }
338
339  #hs_cos_wrapper_widget_1781779179924 .cards__card-link { width:100%; }
340
341  #hs_cos_wrapper_widget_1781779179924 .cards__icon:not(.icon-shadow-border) img {
342    width:auto;
343    height:auto;
344  }
345
346  #hs_cos_wrapper_widget_1781779179924 .cards__icon.icon-shadow-border img {
347    width:100%;
348    height:auto;
349  }
350
351  #hs_cos_wrapper_widget_1781779179924 .cards__card.purple-divider-side {
352    flex-direction:row;
353    align-items:flex-start;
354  }
355
356  #hs_cos_wrapper_widget_1781779179924 .card-1 {
357    width:100% !important;
358    flex-direction:column;
359  }
360
361  #hs_cos_wrapper_widget_1781779179924 .card-1 {}
362
363  #hs_cos_wrapper_widget_1781779179924 .card-1 .cards__icon {}
364
365  #hs_cos_wrapper_widget_1781779179924 .card-1 .cards__title {}
366
367  #hs_cos_wrapper_widget_1781779179924 .card-1 .cards__copy {}
368
369  #hs_cos_wrapper_widget_1781779179924 .card-1 .cards__btn {}
370
371  #hs_cos_wrapper_widget_1781779179924 .card-2 {
372    width:100% !important;
373    flex-direction:column;
374  }
375
376  #hs_cos_wrapper_widget_1781779179924 .card-2 {}
377
378  #hs_cos_wrapper_widget_1781779179924 .card-2 .cards__icon {}
379
380  #hs_cos_wrapper_widget_1781779179924 .card-2 .cards__title {}
381
382  #hs_cos_wrapper_widget_1781779179924 .card-2 .cards__copy {}
383
384  #hs_cos_wrapper_widget_1781779179924 .card-2 .cards__btn {}
385}
386
387</style>
388
389
390<style>
391  #hs_cos_wrapper_widget_1782413235774 .cards {
392  display:flex;
393  flex-direction:row;
394  flex-wrap:wrap;
395  gap:0px;
396  justify-content:flex-start;
397  align-items:stretch;
398  max-width:100%;
399  margin-left:auto;
400  margin-right:auto;
401  padding-top:10px;
402  padding-bottom:50px;
403}
404
405#hs_cos_wrapper_widget_1782413235774 .card-1 {
406  border:none;
407  border-radius:0;
408  flex-direction:column;
409  justify-content:flex-start;
410  align-items:flex-start;
411}
412
413#hs_cos_wrapper_widget_1782413235774 .card-1 .cards__icon {}
414
415#hs_cos_wrapper_widget_1782413235774 .card-1 .cards__title {}
416
417#hs_cos_wrapper_widget_1782413235774 .card-1 .cards__copy {}
418
419#hs_cos_wrapper_widget_1782413235774 .card-1 .cards__btn {}
420
421@media (max-width:767px) {
422  #hs_cos_wrapper_widget_1782413235774 .cards {
423    display:grid !important;
424    grid-template-columns:repeat(1,minmax(0,1fr));
425    gap:0px;
426    justify-items:stretch;
427    margin-left:auto;
428    margin-right:auto;
429    width:auto;
430  }
431
432  #hs_cos_wrapper_widget_1782413235774 .cards__card-link { width:100%; }
433
434  #hs_cos_wrapper_widget_1782413235774 .cards__icon:not(.icon-shadow-border) img {
435    width:auto;
436    height:auto;
437  }
438
439  #hs_cos_wrapper_widget_1782413235774 .cards__icon.icon-shadow-border img {
440    width:100%;
441    height:auto;
442  }
443
444  #hs_cos_wrapper_widget_1782413235774 .cards__card.purple-divider-side {
445    flex-direction:row;
446    align-items:flex-start;
447  }
448
449  #hs_cos_wrapper_widget_1782413235774 .card-1 { flex-direction:column; }
450
451  #hs_cos_wrapper_widget_1782413235774 .card-1 {}
452
453  #hs_cos_wrapper_widget_1782413235774 .card-1 .cards__icon {}
454
455  #hs_cos_wrapper_widget_1782413235774 .card-1 .cards__title {}
456
457  #hs_cos_wrapper_widget_1782413235774 .card-1 .cards__copy {}
458
459  #hs_cos_wrapper_widget_1782413235774 .card-1 .cards__btn {}
460}
461
462</style>
463
464<link rel="stylesheet" href="https://www.lyfgeniahcp.com/hubfs/hub_generated/module_assets/1/214210175037/1784190121954/module_more-topics-module.min.css">
465
466<style>
467  #hs_cos_wrapper_module_17824135797225 .more-topics-container {
468  position:relative;
469  width:100vw;
470  left:50%;
471  right:50%;
472  margin-left:-50vw;
473  margin-right:-50vw;
474  background-color:rgba(1,169,157,1.0);
475}
476
477#hs_cos_wrapper_module_17824135797225 .more-topics .more-topics-heading {
478  background:rgba(0,39,143,1.0);
479  color:rgba(255,255,255,1.0);
480}
481
482#hs_cos_wrapper_module_17824135797225 .more-topics .more-topics-heading,
483#hs_cos_wrapper_module_17824135797225 .more-topics .more-topics-heading * { color:rgba(255,255,255,1.0); }
484
485#hs_cos_wrapper_module_17824135797225 .more-topics .more-topics-links { background:rgba(240,244,252,1.0); }
486
487</style>
488
489<!-- Editor Styles -->
490<style id="hs_editor_style" type="text/css">
491.references-row-0-max-width-section-centering > .row-fluid {
492  max-width: 1140px !important;
493  margin-left: auto !important;
494  margin-right: auto !important;
495}
496.main_content-row-1-max-width-section-centering > .row-fluid {
497  max-width: 1170px !important;
498  margin-left: auto !important;
499  margin-right: auto !important;
500}
501.main_content-row-2-max-width-section-centering > .row-fluid {
502  max-width: 1170px !important;
503  margin-left: auto !important;
504  margin-right: auto !important;
505}
506.main_content-row-3-max-width-section-centering > .row-fluid {
507  max-width: 1140px !important;
508  margin-left: auto !important;
509  margin-right: auto !important;
510}
511.main_content-row-4-max-width-section-centering > .row-fluid {
512  max-width: 1140px !important;
513  margin-left: auto !important;
514  margin-right: auto !important;
515}
516/* HubSpot Styles (default) */
517.cell_17817626007183-padding {
518  padding-left: 15px !important;
519  padding-right: 15px !important;
520}
521.main_content-row-1-background-layers {
522  background-image: linear-gradient(rgba(0, 39, 143, 1), rgba(0, 39, 143, 1)) !important;
523  background-position: left top !important;
524  background-size: auto !important;
525  background-repeat: no-repeat !important;
526}
527.main_content-row-2-padding {
528  padding-top: 7px !important;
529  padding-bottom: 7px !important;
530}
531.main_content-row-2-background-layers {
532  background-image: linear-gradient(rgba(240, 244, 252, 1), rgba(240, 244, 252, 1)) !important;
533  background-position: left top !important;
534  background-size: auto !important;
535  background-repeat: no-repeat !important;
536}
537.cell_17804827121603-padding {
538  padding-left: 15px !important;
539  padding-right: 15px !important;
540}
541.cell_17804857681092-padding {
542  padding-left: 15px !important;
543  padding-right: 15px !important;
544}
545.cell_1781779099680-padding {
546  padding-left: 15px !important;
547  padding-right: 15px !important;
548}
549.cell_17824135797223-padding {
550  padding-left: 15px !important;
551  padding-right: 15px !important;
552}
553/* HubSpot Styles (mobile) */
554@media (max-width: 767px) {
555  .main_content-row-4-padding {
556    padding-bottom: 0px !important;
557  }
558}
559</style>
560    
561
562    
563    <link rel="canonical" href="https://www.lyfgeniahcp.com">
564
565
566<meta property="og:url" content="https://www.lyfgeniahcp.com">
567<meta name="twitter:card" content="summary">
568<meta http-equiv="content-language" content="en">
569
570
571
572
573
574
575
576<!-- hcp-home-hero-mobile-center -->
577<style>
578/* Mobile: the hero text column carries a desktop `pl-0` (flush-left in the split
579   layout) and renders ~30px narrow, so the centered heading landed off-center to the
580   left. Make the column full-width with symmetric 15px padding on mobile so the copy
581   centers in the viewport (matches production). */
582@media (max-width: 767px) {
583  #hs_cos_wrapper_widget_1780477538954 .col-md-6.pl-0 {
584    width: 100vw !important;
585    max-width: 100vw !important;
586    margin-left: 0 !important;
587    padding-left: 15px !important;
588    padding-right: 15px !important;
589    box-sizing: border-box !important;
590  }
591}
592</style>
593
594<meta name="generator" content="HubSpot"></head>
595
596<body>
597
598  <div id="hs_cos_wrapper_hcp_honesty_modal" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
599
600<div id="before-header">
601  <div class="modal modal-gate fade" data-keyboard="true" id="honesty-box" role="dialog" tabindex="-1" aria-hidden="true">
602    <div class="modal-dialog modal-dialog-centered" role="document">
603      <div class="modal-content">
604        <div class="modal-header">
605          <h5 class="modal-title">&nbsp;</h5>
606          
607          <button aria-label="Close" class="close" data-dismiss="modal" type="button">
608            <span aria-hidden="true"><img alt="Close" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/close-modal.png"></span>
609          </button>
610          
611        </div>
612        <div class="modal-body">
613          
614          <h2 class="honesty-heading">Are you a US healthcare professional?</h2>
615          
616          
617          <div class="honesty-body"><p>You are about to enter a page that is intended for US healthcare professionals only.</p><p>Please confirm that you are a US healthcare professional.</p></div>
618          
619          <button aria-label="I am a US healthcare professional" class="btn modal-gate-confirm honesty-confirm" data-dismiss="modal" type="button">I am a US healthcare professional</button>
620          
621          <a class="ext-link-out honesty-alt" href="https://www.lyfgenia.com/?hsLang=en" rel="noopener noreferrer">Visit the patient &amp; caregiver site</a>
622          
623        </div>
624      </div>
625    </div>
626  </div>
627</div>
628
629<script>
630(function () {
631  'use strict';
632  var STORAGE_KEY = "modalGateConfirmation";
633
634  function getFlag() {
635    try { return sessionStorage.getItem(STORAGE_KEY) === '1'; }
636    catch (e) { return false; }
637  }
638  function setFlag() {
639    try { sessionStorage.setItem(STORAGE_KEY, '1'); } catch (e) {}
640  }
641
642  function showModal(modal) {
643    if (typeof jQuery !== 'undefined' && jQuery.fn && jQuery.fn.modal) {
644      jQuery(modal).modal({ backdrop: 'static', keyboard: false });
645      jQuery(modal).modal('show');
646      return;
647    }
648    modal.classList.add('show');
649    modal.style.display = 'block';
650    document.body.classList.add('modal-open');
651    var backdrop = document.createElement('div');
652    backdrop.className = 'modal-backdrop fade show';
653    backdrop.id = 'honesty-box-backdrop';
654    document.body.appendChild(backdrop);
655  }
656
657  function hideModal(modal) {
658    if (typeof jQuery !== 'undefined' && jQuery.fn && jQuery.fn.modal) {
659      jQuery(modal).modal('hide');
660      return;
661    }
662    modal.classList.remove('show');
663    modal.style.display = 'none';
664    document.body.classList.remove('modal-open');
665    var backdrop = document.getElementById('honesty-box-backdrop');
666    if (backdrop) backdrop.parentNode.removeChild(backdrop);
667  }
668
669  function init() {
670    var modal = document.getElementById('honesty-box');
671    if (!modal) return;
672
673    // Skip auto-fire inside iframes (HubSpot page editor preview, etc.) so editors
674    // can interact with sections/modules without the gate blocking them.
675    try {
676      if (window.self !== window.top) {
677        modal.style.display = 'none';
678        return;
679      }
680    } catch (e) { /* cross-origin top — assume embed, skip */
681      modal.style.display = 'none';
682      return;
683    }
684
685    try {
686      var params = new URLSearchParams(window.location.search);
687      if (params.get('confirmation') === 'true') setFlag();
688    } catch (e) {}
689
690    if (getFlag()) {
691      modal.style.display = 'none';
692      return;
693    }
694
695    showModal(modal);
696    document.body.classList.add('honesty-open');
697
698    var hideTargets = ['#skip-link', '#site-header', '#content', '#footer'];
699    hideTargets.forEach(function (sel) {
700      var el = document.querySelector(sel);
701      if (el) el.setAttribute('aria-hidden', 'true');
702    });
703    modal.setAttribute('aria-hidden', 'false');
704
705    var confirmBtn = modal.querySelector('.modal-gate-confirm');
706    if (confirmBtn) {
707      confirmBtn.addEventListener('click', function () {
708        setFlag();
709        hideTargets.forEach(function (sel) {
710          var el = document.querySelector(sel);
711          if (el) el.setAttribute('aria-hidden', 'false');
712        });
713        modal.setAttribute('aria-hidden', 'true');
714        hideModal(modal);
715        document.body.classList.remove('honesty-open');
716      });
717    }
718  }
719
720  function waitForReady(retries) {
721    if (typeof jQuery !== 'undefined' && jQuery.fn && jQuery.fn.modal) {
722      init(); return;
723    }
724    if (retries > 100) { init(); return; }
725    setTimeout(function () { waitForReady(retries + 1); }, 100);
726  }
727
728  if (document.readyState === 'loading') {
729    document.addEventListener('DOMContentLoaded', function () { waitForReady(0); });
730  } else {
731    waitForReady(0);
732  }
733})();
734</script>
734</div>
735
736  
737      <header id="site-header">
738        <div id="hs_cos_wrapper_disclaimer_bar" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module"><div class="strip-component sticky-header p-0">
739  <div class="strip-component bg-tertiary py-0 site-disclaimer">
740    <div class="grid-component container">
741      <div class="row">
742        <div class="col-12 py-2 py-md-1 px-1">
743          This website is developed by Genetix Biotherapeutics Inc. and is intended for US healthcare professionals only. <a class="text-primary" href="https://www.lyfgenia.com?hsLang=en">Visit Patient Site</a>
744        </div>
745      </div>
746    </div>
747  </div>
748</div></div>
749        <nav class="navbar" id="navbar">
750          <div id="hs_cos_wrapper_header_branding" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
751
752
753
754
755
756
757
758
759
760
761
762
763<div class="container secondary-menu-wrapper">
764  <div class="row">
765    <div class="col-12 no-top-padding">
766      <a class="text-primary" href="https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Lyfgenia/LYFGENIA_Prescribing_Information.pdf" rel="noopener noreferrer" target="_blank">Prescribing Information</a><span class="d-none d-md-inline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><a class="text-primary d-none d-md-inline" href="/important-safety-information?hsLang=en">Important Safety Information</a><span class="d-none d-md-inline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><a class="text-primary" href="/find-a-qualified-treatment-center?hsLang=en">Qualified Treatment Centers</a>
767    </div>
768  </div>
769</div>
770
771
772<div class="container branding-wrapper">
773  <div class="branding">
774    <a href="/?hsLang=en">
775      <img alt="LYFGENIA (lovotibeglogene autotemcel) logo" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/logos/lyfgenia-logo.svg">
776    </a>
777  </div>
778  <div class="global-header-banner"></div>
779  <div class="tertiary-menu ml-auto">
780    <ul>
781      
782      <li>
783        <a class="btn link-videos IBMPlexSans-SemiBold" href="/videos-on-demand?hsLang=en" target="">
784          Explore Videos&nbsp;&nbsp;<i class="fas fa-chevron-right"></i>
785        </a>
786      </li>
787      
788      
789      <li>
790        <a class="btn link-representative IBMPlexSans-SemiBold" href="/request-a-representative?hsLang=en" target="">
791          Request a Representative&nbsp;&nbsp;<i class="fas fa-chevron-right"></i>
792        </a>
793      </li>
794      
795    </ul>
796  </div>
797  <button aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation" class="navbar-toggler collapsed" id="toggle-menu" type="button">
798    <i class="fas"></i>
799    <span>Menu</span>
800  </button>
801</div></div>
802          <div id="hs_cos_wrapper_header_nav" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
803
804<div class="menu-wrapper collapse navbar-collapse" id="navbarSupportedContent">
805  <a href="/?hsLang=en"><img class="mobile-menu-logo" alt="Lyfgenia" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/logos/lyfgenia-logo.svg" width="150" height="62"></a>
806  
807  <div class="primary-menu-left"></div>
808  <div class="primary-menu-right"></div>
809  <div class="primary-menu">
810    <div class="container">
811      <ul class="navbar-nav">
812        
813        
814        <li class="nav-item level-1">
815          <a class="level-1-link navbar-menu-button" href="/mechanism-of-action?hsLang=en" target="">
816            <i class=""></i>
817            MOA
818          </a>
819          
820        </li>
821        
822        
823        <li class="nav-item level-1">
824          <a class="level-1-link" href="/clinical-trials?hsLang=en" target="">
825            <i class=""></i>
826            Studies + Results
827          </a>
828          
829          <div class="sub-menu" id="submenu-2">
830            <div class="sub-menu-column">
831              <ul class="">
832                
833                <li>
834                  <a class="level-2-link" href="/clinical-trials?hsLang=en" target="">
835                    <i class=""></i>
836                    Clinical Results
837                  </a>
838                  <ul></ul>
839                </li>
840                
841                <li>
842                  <a class="level-2-link" href="/clinical-trials/safety?hsLang=en" target="">
843                    <i class=""></i>
844                    Safety
845                  </a>
846                  <ul></ul>
847                </li>
848                
849              </ul>
850            </div>
851          </div>
852          
853        </li>
854        
855        
856        <li class="nav-item level-1">
857          <a class="level-1-link" href="/treatment-pathway?hsLang=en" target="">
858            <i class=""></i>
859            Treatment Pathway
860          </a>
861          
862        </li>
863        
864        
865        <li class="nav-item level-1">
866          <a class="level-1-link" href="/support?hsLang=en" target="">
867            <i class=""></i>
868            Support + Resources
869          </a>
870          
871        </li>
872        
873        
874        <li class="nav-item level-1">
875          <a class="level-1-link" href="/faqs?hsLang=en" target="">
876            <i class=""></i>
877            FAQs
878          </a>
879          
880        </li>
881        
882      </ul>
883    </div>
884  </div>
885</div></div>
886        </nav>
887      </header>
888
889      
890      <main id="content" tabindex="-1">
891        
892        <div class="container-fluid">
893<div class="row-fluid-wrapper">
894<div class="row-fluid">
895<div class="span12 widget-span widget-type-cell " style="" data-widget-type="cell" data-x="0" data-w="12">
896
897<div class="row-fluid-wrapper row-depth-1 row-number-1 dnd-section">
898<div class="row-fluid ">
899<div class="span12 widget-span widget-type-cell dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
900
901<div class="row-fluid-wrapper row-depth-1 row-number-2 dnd-row">
902<div class="row-fluid ">
903<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
904<div id="hs_cos_wrapper_widget_1780477538954" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929  
930  
931  
932  
933  
934    <div class="strip-component py-0 lyf-custom-banner d-none d-md-block hero-fullwidth" style="background-image: url(https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_image_Hero-D-2x.jpg)" role="img" aria-label="lyf_hcp_image_Hero-D-2x">
935      <div class="grid-component container container-wide">
936        <div class="row">
937          <div class="col-md-6 pl-0">
938            <div class="text-center">
939              <div class="banner-text-holder">
940<div class="banner-text-top text-white">
941<p class="intro-text">Someday, life with sickle cell disease could be different.</p>
942<p class="intro-text">Someday you could help make gene therapy a reality for your patients.</p>
943<p class="intro-headline"><span class="banner-text-large">Someday</span><br>is <span class="banner-text-large">Today</span></p>
944<p><img src="https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_icon_wave-large.svg" width="168" height="10" loading="lazy" alt="lyf_hcp_icon_wave-large" style="height: auto; max-width: 100%; width: 168px;"></p>
945</div>
946<div class="banner-text-bottom">
947<p class="intro-subheadline mb-3 text-white">LYFGENIA™ is the longest-studied* approved <br class="d-none d-lg-block">gene therapy for sickle cell disease<sup>1,2</sup></p>
948<p class="font-small text-white" style="margin-bottom: 50px;">*The key registrational clinical trial that <br class="d-none d-md-block">evaluated LYFGENIA started in February 2015.<sup>1</sup></p>
949</div>
950</div>
951              
952                
953                
954                
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971  
972  
973  
974  <a class="btn btn-secondary arrow" href="/clinical-trials?hsLang=en">See results from clinical trials</a>
975
976              
977            </div>
978          </div>
979          <div class="col-md-6"></div>
980        </div>
981      </div>
982      
983        <div class="banner-caption">
984          <div class="actor-portrayal"><span class="text-white">Actor Portrayals</span></div>
985        </div>
986      
987    </div>
988  
989  
990  
991  
992  
993    <div class="strip-component py-0 lyf-custom-banner d-block d-md-none hero-fullwidth" style="background-image: url(https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_image_Hero-M-2x.jpg)" role="img" aria-label="lyf_hcp_image_Hero-D-2x">
994      <div class="grid-component container container-wide">
995        <div class="row">
996          <div class="col-md-6 pl-0">
997            <div class="text-center">
998              <div class="banner-text-holder">
999<div class="banner-text-top text-white">
1000<p class="intro-text">Someday, life with sickle cell disease could be different.</p>
1001<p class="intro-text">Someday you could help make gene therapy a reality for your patients.</p>
1002<p class="intro-headline"><span class="banner-text-large">Someday</span><br>is <span class="banner-text-large">Today</span></p>
1003<p><img src="https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_icon_wave-large.svg" width="168" height="10" loading="lazy" alt="lyf_hcp_icon_wave-large" style="height: auto; max-width: 100%; width: 168px;"></p>
1004</div>
1005<div class="banner-text-bottom">
1006<p class="intro-subheadline mb-3 text-white">LYFGENIA™ is the longest-studied* approved <br class="d-none d-lg-block">gene therapy for sickle cell disease<sup>1,2</sup></p>
1007<p class="font-small text-white" style="margin-bottom: 50px;">*The key registrational clinical trial that <br class="d-none d-md-block">evaluated LYFGENIA started in February 2015.<sup>1</sup></p>
1008</div>
1009</div>
1010              
1011                
1012                
1013                
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030  
1031  
1032  
1033  <a class="btn btn-secondary arrow" href="/clinical-trials?hsLang=en">See results from clinical trials</a>
1034
1035              
1036            </div>
1037          </div>
1038          <div class="col-md-6"></div>
1039        </div>
1040      </div>
1041      
1042        <div class="banner-caption">
1043          <div class="actor-portrayal"><span class="text-white">Actor Portrayals</span></div>
1044        </div>
1045      
1046    </div>
1047  
1048
1049
1050</div>
1051
1052</div><!--end widget-span -->
1053</div><!--end row-->
1054</div><!--end row-wrapper -->
1055
1056</div><!--end widget-span -->
1057</div><!--end row-->
1058</div><!--end row-wrapper -->
1059
1060<div class="row-fluid-wrapper row-depth-1 row-number-3 main_content-row-1-background-layers main_content-row-1-background-color dnd-section main_content-row-1-max-width-section-centering">
1061<div class="row-fluid ">
1062<div class="span12 widget-span widget-type-cell cell_17804827121603-padding dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
1063
1064<div class="row-fluid-wrapper row-depth-1 row-number-4 dnd-row">
1065<div class="row-fluid ">
1066<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1067<div id="hs_cos_wrapper_widget_1780482725784" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094<div id="widget_1780482725784" class="cards">
1095  
1096  
1097  
1098  
1099  
1100  
1101  <div class="cards__card card-1">
1102
1103    
1104
1105    
1106
1107    <div class="cards__content">
1108
1109    
1110    
1111
1112    <div class="cards__copy"><div class="strip-component bg-primary">
1113<div class="grid-component container">
1114<div class="row">
1115<div class="col-md-12 py-2">
1116<div class="text-white">
1117<p class="mb-0 pt-4 pt-lg-0">LYFGENIA is an autologous hematopoietic stem cell-based gene therapy <span class="IBMPlexSans-Bold">indicated for the treatment of patients 12 years of age or older with sickle cell disease</span> and a history of vaso-occlusive events.<sup>2</sup></p>
1118</div>
1119</div>
1120</div>
1121</div>
1122</div></div>
1123
1124    
1125
1126    </div>
1127
1128    
1129
1130    
1131
1132  </div>
1133  
1134  
1135</div>
1136</div>
1137
1138</div><!--end widget-span -->
1139</div><!--end row-->
1140</div><!--end row-wrapper -->
1141
1142</div><!--end widget-span -->
1143</div><!--end row-->
1144</div><!--end row-wrapper -->
1145
1146<div class="row-fluid-wrapper row-depth-1 row-number-5 dnd-section main_content-row-2-background-color main_content-row-2-padding main_content-row-2-max-width-section-centering main_content-row-2-background-layers">
1147<div class="row-fluid ">
1148<div class="span12 widget-span widget-type-cell cell_17804857681092-padding dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
1149
1150<div class="row-fluid-wrapper row-depth-1 row-number-6 dnd-row">
1151<div class="row-fluid ">
1152<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1153<div id="hs_cos_wrapper_widget_1780485981048" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module widget-type-rich_text" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module"><span id="hs_cos_wrapper_widget_1780485981048_" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_rich_text" style="" data-hs-cos-general-type="widget" data-hs-cos-type="rich_text"><div class="strip-component bg-tertiary py-0">
1154<div class="grid-component container">
1155<div class="row">
1156<div class="col-md-12 py-0">
1157<div class="panel-group FAQaccordion limitations-accordion" id="accordion-limitations">
1158<div class="panel panel-default question">
1159<div class="panel-heading h5 text-primary pt-0">
1160<div class="panel-title question-title"><a class="question-link collapsed" data-bs-toggle="collapse" data-bs-target="#collapse-limitations" aria-expanded="false" aria-controls="collapse-limitations" tabindex="0" role="button"> <span class="IBMPlexSans-Bold" style="font-size: 16px;">Limitations of Use</span> </a></div>
1161</div>
1162<div class="panel-collapse collapse" id="collapse-limitations">
1163<div class="panel-body-mask">
1164<div class="panel-body question-body pb-1">Following treatment with LYFGENIA, patients with α-thalassemia trait (-α3.7/-α3.7) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α-globin gene deletions.<sup>2</sup></div>
1165</div>
1166</div>
1167</div>
1168</div>
1169</div>
1170</div>
1171</div>
1172</div></span></div>
1173
1174</div><!--end widget-span -->
1175</div><!--end row-->
1176</div><!--end row-wrapper -->
1177
1178</div><!--end widget-span -->
1179</div><!--end row-->
1180</div><!--end row-wrapper -->
1181
1182<div class="row-fluid-wrapper row-depth-1 row-number-7 dnd-section main_content-row-3-max-width-section-centering">
1183<div class="row-fluid ">
1184<div class="span12 widget-span widget-type-cell cell_1781779099680-padding dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
1185
1186<div class="row-fluid-wrapper row-depth-1 row-number-8 dnd-row">
1187<div class="row-fluid ">
1188<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1189<div id="hs_cos_wrapper_widget_1781779179924" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216<div id="widget_1781779179924" class="cards">
1217  
1218  
1219  
1220  
1221  
1222  
1223  <div class="cards__card card-1">
1224
1225    
1226
1227    
1228
1229    <div class="cards__content">
1230
1231    
1232    
1233
1234    <div class="cards__copy"><div class="py-0 py-md-3 mb-5 mb-md-0">
1235<div class="content-tile no-icon content-tile-blue-bg"><img alt="" class="content-tile-img" src="https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_icon_DNA.svg">
1236<div class="content-tile-content">
1237<p class="IBMPlexSans-Bold text-septenary" style="font-size: 16px;">HOW IT WORKS</p>
1238<h1 class="h1 content-tile-title IBMPlexSerif-Medium text-black">LYFGENIA is a single dose autologous gene addition therapy<sup>2</sup></h1>
1239<div class="content-tile-text pb-1 pb-md-4">Designed to produce anti-sickling adult hemoglobin (HbA<sup>T87Q</sup>) to potentially decrease or stop vaso-occlusive events (VOEs).<sup>2†‡§</sup></div>
1240<div class="d-flex justify-content-start"><a class="btn btn-primary medium" href="/mechanism-of-action?hsLang=en">Learn how LYFGENIA works</a></div>
1241</div>
1242</div>
1243</div></div>
1244
1245    
1246
1247    </div>
1248
1249    
1250
1251    
1252
1253  </div>
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  <div class="cards__card card-2">
1262
1263    
1264
1265    
1266
1267    <div class="cards__content">
1268
1269    
1270    
1271
1272    <div class="cards__copy"><div class="py-0 py-md-3">
1273<div class="content-tile no-icon content-tile-blue-bg"><img alt="" class="content-tile-img" src="https://www.lyfgeniahcp.com/hubfs/lyfgeniahcp/images/lyf_hcp_icon_Cell-Red.svg">
1274<div class="content-tile-content"><i class="content-tile-icon"></i>
1275<p class="IBMPlexSans-Bold text-septenary" style="font-size: 16px;">CLINICAL EFFECTIVENESS</p>
1276<h1 class="h1 content-tile-title IBMPlexSerif-Medium text-black">A one-time transformational sickle cell disease (SCD) gene therapy with the potential to decrease or stop VOEs<sup>2</sup></h1>
1277<div class="content-tile-text pb-1 mb-5">88% (n=28/32, CI: 71, 97) of evaluable patients in Study 1-C achieved complete resolution of VOEs (VOE-CR) between 6 and 18 months after infusion of LYFGENIA.<sup>2†‡§</sup></div>
1278<div class="d-flex justify-content-start"><a class="btn btn-primary medium" href="/clinical-trials?hsLang=en">See the efficacy data</a></div>
1279</div>
1280</div>
1281</div></div>
1282
1283    
1284
1285    </div>
1286
1287    
1288
1289    
1290
1291  </div>
1292  
1293  
1294</div>
1295</div>
1296
1297</div><!--end widget-span -->
1298</div><!--end row-->
1299</div><!--end row-wrapper -->
1300
1301<div class="row-fluid-wrapper row-depth-1 row-number-9 dnd-row">
1302<div class="row-fluid ">
1303<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1304<div id="hs_cos_wrapper_widget_1782413235774" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331<div id="widget_1782413235774" class="cards">
1332  
1333  
1334  
1335  
1336  
1337  
1338  <div class="cards__card card-1 container-narrow">
1339
1340    
1341
1342    
1343
1344    <div class="cards__content">
1345
1346    
1347    
1348
1349    <div class="cards__copy"><div style="font-family; lato-regular; font-size: 10px; line-height: 12px;">
1350<p class="mb-2">VOE-CR = elimination of VOEs between 6 and 18 months post infusion.<sup>2</sup></p>
1351<p class="mb-2"><span class="sup-text"><sup style="top: 3px;">†</sup>VOEs were defined as any of the following events requiring evaluation at a medical facility: an episode of acute pain with no medically determined cause other than vaso-occlusion, lasting more than 2 hours, acute chest syndrome, acute hepatic sequestration, or acute splenic sequestration.</span><sup>2</sup></p>
1352<p class="mb-2"><span class="sup-text"><sup style="top: 3px;">‡</sup>After the primary evaluation period to last follow-up, 4 of 28 patients who achieved VOE-CR experienced VOEs.</span><sup>2</sup></p>
1353<p><span class="sup-text"><sup style="top: 3px;">§</sup>The efficacy of LYFGENIA was studied in a single-arm, 24-month, open-label, multicenter Phase 1/2 study (Study 1-C) and a long-term follow-up study. In Study 1-C, 32 patients with a history of at least 4 VOEs in the 24 months prior to informed consent were evaluated for VOEs.</span><sup>2</sup></p>
1354</div></div>
1355
1356    
1357
1358    </div>
1359
1360    
1361
1362    
1363
1364  </div>
1365  
1366  
1367</div>
1368</div>
1369
1370</div><!--end widget-span -->
1371</div><!--end row-->
1372</div><!--end row-wrapper -->
1373
1374</div><!--end widget-span -->
1375</div><!--end row-->
1376</div><!--end row-wrapper -->
1377
1378<div class="row-fluid-wrapper row-depth-1 row-number-10 main_content-row-4-padding dnd-section main_content-row-4-max-width-section-centering">
1379<div class="row-fluid ">
1380<div class="span12 widget-span widget-type-cell cell_17824135797223-padding dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
1381
1382<div class="row-fluid-wrapper row-depth-1 row-number-11 dnd-row">
1383<div class="row-fluid ">
1384<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1385<div id="hs_cos_wrapper_module_17824135797225" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395<div class="strip-component more-topics-container pt-5 more-topics-container-home pb-5 pb-md-9">
1396  <div class="grid-component container more-topics more-topics-home">
1397    <div class="row">
1398      <div class="col-md-6 more-topics-heading">
1399        <div class="more-topics-heading-text">
1400          
1401          <p class="IBMPlexSans-SemiBold text-white" style="color: #ffffff; line-height: 22px; background-color: #00278f;">Genetix CARES</p>
1402<h1 style="line-height: 40px; color: #ffffff; background-color: #00278f;">Support that never stops</h1>
1403<p>&nbsp;</p>
1404<p style="line-height: 22px; color: #ffffff; background-color: #00278f;">Even before LYFGENIA is prescribed, your patients can enroll in and receive access to<span> </span><a href="https://www.genetixcares.com/?hsLang=en">Genetix CARES</a>—a program that provides a range of support from helping to identify Qualified Treatment Center options for consultation to understanding insurance benefits and the process for prior authorization.</p>
1405<p style="line-height: 22px; color: #ffffff; background-color: #00278f;">Patient Navigators are here to help with education, access, and logistics throughout the decision process and beyond.</p>
1406<p><img src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_hcp_icon_mail-white.svg" style="vertical-align: middle; height: auto; color: #ffffff; background-color: #00278f; width: 50px;"> <a href="mailto:[email protected]">[email protected]</a></p>
1407<p><img src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_hcp_icon_phone-white.svg" style="vertical-align: middle; height: auto; color: #ffffff; background-color: #00278f; width: 50px;"> <a href="tel:1-833-888-6378">1-833-888-6378</a></p>
1408        </div>
1409      </div>
1410      <div class="col-md-6 more-topics-links">
1411        <div class="more-topics-links-text">
1412          
1413            
1414            
1415            
1416            <div><a class="btn btn-quaternary support mb-5" href="https://www.lyfgeniahcp.com/support?hsLang=en">Genetix Support + Resources</a></div>
1417          
1418            
1419            
1420            
1421            <div><a class="btn btn-quaternary qtc" href="https://www.lyfgeniahcp.com/find-a-qualified-treatment-center?hsLang=en">Find a Qualified Treatment Center (QTC)</a></div>
1422          
1423        </div>
1424      </div>
1425    </div>
1426  </div>
1427</div></div>
1428
1429</div><!--end widget-span -->
1430</div><!--end row-->
1431</div><!--end row-wrapper -->
1432
1433</div><!--end widget-span -->
1434</div><!--end row-->
1435</div><!--end row-wrapper -->
1436
1437</div><!--end widget-span -->
1438</div>
1439</div>
1440</div>
1441        
1442      </main>
1443
1444      
1445      <footer class="footer" id="footer">
1446        
1447        <div id="hs_cos_wrapper_signup" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1448
1449
1450<div class="signup-outer" style="
1451  
1452    background-color: rgba(240, 244, 252, 1.0);
1453  
1454  padding: 40px 0px 40px 0px;
1455  margin: 0px 0px 0px 0px;
1456">
1457  <div class="grid-component container">
1458    <div class="row">
1459      <div class="col-md-12">
1460        <div class="signup-wrapper">
1461          <div class="row">
1462            <div class="col-2 text-center pb-0 px-0 px-md-3 signup-icon-col">
1463              
1464              <img class="d-none d-lg-block mb-3" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_hcp_icon_mail-blue.svg" alt="SignUp icon" style="height:125px; width:125px;" loading="lazy">
1465              <img class="d-none d-md-block d-lg-none mb-3" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_hcp_icon_mail-blue.svg" alt="SignUp icon" style="height:85px; width:85px;" loading="lazy">
1466              <img class="d-block d-md-none" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/lyf_hcp_icon_mail-blue.svg" alt="SignUp icon" style="height:50px; width:50px;" loading="lazy">
1467            </div>
1468            <div class="col-10 my-auto pl-3 pb-0 pr-0 pr-md-3 signup-text-col">
1469              <p class="signup-heading d-none d-md-block" style="font-size: 32px; line-height: 37px; color: #00278f; font-family: IBMPlexSerif-Regular, serif; margin: 0;">
1470                Sign up here to receive emails with more LYFGENIA information and resources</p>
1471              <p class="signup-heading d-block d-md-none" style="font-size: 24px; line-height: 28px; color: #00278f; font-family: IBMPlexSerif-Regular, serif; margin: 0;">
1472                Sign up here to receive emails with more LYFGENIA information and resources</p>
1473              
1474            </div>
1475          </div>
1476          
1477          
1478          <div class="row signup-form-row">
1479            
1480            <div class="col-12 signup-form" id="signup-form-signup" style="display: block;">
1481              
1482              <span id="hs_cos_wrapper_signup_" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_form" style="" data-hs-cos-general-type="widget" data-hs-cos-type="form"><h3 id="hs_cos_wrapper_signup_{{ name }}_title" class="hs_cos_wrapper form-title" data-hs-cos-general-type="widget_field" data-hs-cos-type="text"></h3>
1483
1484<div id="hs_form_target_signup_signup" class="hs-form-html" data-form-id="3989ebd8-3049-4752-bebb-7700b4ab1eb0" data-portal-id="50895703" data-region="na1"></div>
1485
1486
1487
1488
1489
1490</span>
1491            </div>
1492          </div>
1493          
1494        </div>
1495      </div>
1496    </div>
1497
1498    
1499    
1499<script>
1500      (function () {
1501        var btn = document.getElementById('btn-signup-signup');
1502        var formContainer = document.getElementById('signup-form-signup');
1503        if (btn && formContainer) {
1504          btn.addEventListener('click', function () {
1505            formContainer.style.display = 'block';
1506            btn.style.display = 'none';
1507          });
1508        }
1509      })();
1510    </script>
1510
1511    
1512  </div>
1513</div>
1514</div>
1515        
1515<script>
1516          if (window.location.pathname === '/' || window.location.pathname === '') {
1517            document.addEventListener('DOMContentLoaded', function () {
1518              var form = document.querySelector('[id^="signup-form-"]');
1519              var btn  = document.querySelector('[id^="btn-signup-"]');
1520              if (form) form.style.display = 'block';
1521              if (btn)  btn.style.display  = 'none';
1522            });
1523          }
1524        </script>
1524
1525
1526        <div id="hs_cos_wrapper_isi" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1527
1528
1529
1530
1531
1532<div class="important-information-banner">
1533
1534  
1535  <div class="full-content container">
1536    
1537  <div class="row">
1538    <div class="col-lg-7 col-md-7 col-sm-12 pb-0 pb-lg-3 pt-3">
1539      <h2 class="IBMPlexSans-Bold mb-2 d-none d-md-block" style="color:#218282; font-size:20px;">Important Safety Information</h2>
1540      <h2 class="IBMPlexSans-Bold mb-2 d-block d-md-none expanded-hide" style="color:#218282; font-size:20px; padding-top:5px; margin-top:-15px; line-height: 1.2;">Important Safety<br> Information</h2>
1541      <h2 class="IBMPlexSans-Bold mb-2 d-block d-md-none expanded-show" style="color:#218282; font-size:20px; padding-top:5px; margin-top:-15px; line-height: 1.2;">Important Safety<br>Information and Indication</h2>
1542      
1543      <p class="IBMPlexSans-Bold mb-0 text-primary">Boxed WARNING: HEMATOLOGIC MALIGNANCY</p><p class="IBMPlexSans-Bold mb-2 text-black" style="line-height:22px;">Hematologic malignancy has occurred in patients treated with LYFGENIA. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through integration site analysis at Months 6, 12, and as warranted.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hematologic Malignancy</p><p class="mb-2" style="line-height:22px;">Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A). At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML). One patient with <span class="text-nowrap">α-thalassemia</span> trait (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS).</p><p class="mb-2" style="line-height:22px;">The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy. Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population.</p><p class="mb-2" style="line-height:22px;">Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.</p><p class="mb-2" style="line-height:22px;">In the event that a malignancy occurs, contact Genetix Biotherapeutics at 1-833-999-6378 for reporting and to obtain instructions on collection of samples for testing.</p><p class="mb-2" style="line-height:22px;"><span style="text-decoration: underline;">Post-Marketing Long Term Follow-Up Study:</span> Patients who intend to receive treatment with LYFGENIA are encouraged to enroll in the study, as available, to assess the long-term safety of LYFGENIA and the risk of malignancies occurring after treatment with LYFGENIA by calling Genetix Biotherapeutics at 1-833-999-6378. The study includes monitoring (at pre-specified intervals) for clonal expansion.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Delayed Platelet Engraftment</p><p class="mb-2" style="line-height:22px;">Delayed platelet engraftment has been observed with LYFGENIA. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in patients with prolonged thrombocytopenia. Two patients (4%) required more than 100 days post treatment with LYFGENIA to achieve platelet engraftment.</p><p class="mb-2" style="line-height:22px;">Patients should be made aware of the risk of bleeding until platelet recovery has been achieved. Monitor patients for thrombocytopenia and bleeding according to standard guidelines. Conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved. Perform blood cell count determination and other appropriate testing whenever clinical symptoms suggestive of bleeding arise.</p>
1543<p class="IBMPlexSans-Bold mb-2 text-primary">Neutrophil Engraftment Failure</p><p class="mb-2" style="line-height:22px;">There is a potential risk of neutrophil engraftment failure after treatment with LYFGENIA. Neutrophil engraftment failure is defined as failure to achieve three consecutive absolute neutrophil counts (ANC) ≥ 0.5 × 10<sup>9</sup> cells/L obtained on different days by Day 43 after infusion of LYFGENIA. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a patient treated with LYFGENIA, provide rescue treatment with the back-up collection of CD34+ cells.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Insertional Oncogenesis</p><p class="mb-2" style="line-height:22px;">There is a potential risk of lentiviral vector-mediated insertional oncogenesis after treatment with LYFGENIA.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hypersensitivity Reactions</p><p class="mb-2" style="line-height:22px;">Allergic reactions may occur with the infusion of LYFGENIA. The dimethyl sulfoxide (DMSO) or dextran 40 in LYFGENIA may cause hypersensitivity reactions, including anaphylaxis.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Anti-retroviral Use</p><p class="mb-2" style="line-height:22px;">Patients should not take prophylactic HIV anti-retroviral medications for at least one month prior to mobilization and until all cycles of apheresis are completed. There are some long-acting anti-retroviral medications that may require a longer duration of discontinuation for elimination of the medication. If a patient is taking anti-retrovirals for HIV prophylaxis, confirm a negative test for HIV before beginning mobilization and apheresis of CD34+ cells.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hydroxyurea Use</p><p class="mb-2" style="line-height:22px;">Patients should not take hydroxyurea for at least 2 months prior to mobilization and until all cycles of apheresis are completed. If hydroxyurea is administered between mobilization and conditioning, discontinue 2 days prior to initiation of conditioning.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Iron Chelation</p><p class="mb-2" style="line-height:22px;">Drug-drug interactions between iron chelators and the mobilization process and myeloablative conditioning agent must be considered. Iron chelators should be discontinued at least 7 days prior to initiation of mobilization or conditioning. Do not administer myelosuppressive iron chelators (e.g., deferiprone) for 6 months post-treatment with LYFGENIA. Non-myelosuppressive iron chelation should be restarted no sooner than 3 months after LYFGENIA infusion. Phlebotomy can be used in lieu of iron chelation, when appropriate.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Interference with PCR-based Testing</p><p class="mb-2" style="line-height:22px;">Patients who have received LYFGENIA are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to integrated BB305 LVV proviral DNA, resulting in a possible false-positive PCR assay test result for HIV. Therefore, patients who have received LYFGENIA should not be screened for HIV infection using a PCR-based assay.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Adverse Reactions</p><p class="mb-2" style="line-height:22px;">The most common adverse reactions ≥ Grade 3 (incidence ≥ 20%) were stomatitis, thrombocytopenia, neutropenia, febrile neutropenia, anemia, and leukopenia.</p><p class="mb-2" style="line-height:22px;">Three patients died during LYFGENIA clinical trials; one from sudden cardiac death due to underlying disease and two from acute myeloid leukemia who were treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A).</p><p class="IBMPlexSans-Bold mb-2 text-primary">Pregnancy/Lactation</p><p class="mb-2" style="line-height:22px;">Advise patients of the risks associated with myeloablative conditioning agents, including on pregnancy and fertility.</p><p class="mb-2" style="line-height:22px;">LYFGENIA should not be administered to women who are pregnant, and pregnancy after LYFGENIA infusion should be discussed with the treating physician.</p><p class="mb-2" style="line-height:22px;">LYFGENIA is not recommended for women who are breastfeeding, and breastfeeding after LYFGENIA infusion should be discussed with the treating physician.</p>
1543<p class="IBMPlexSans-Bold mb-2 text-primary">Females and Males of Reproductive Potential</p><p class="mb-2" style="line-height:22px;">A negative serum pregnancy test must be confirmed prior to the start of mobilization and re-confirmed prior to conditioning procedures and before LYFGENIA administration.</p><p class="mb-2" style="line-height:22px;">Women of childbearing potential and men capable of fathering a child should use an effective method of contraception (intra-uterine device or combination of hormonal and barrier contraception) from start of mobilization through at least 6 months after administration of LYFGENIA.</p><p class="mb-2" style="line-height:22px;">Advise patients of the options for fertility preservation.</p><p class="IBMPlexSans-Bold text-black">Please see full <a class="text-link text-primary Lato-Bold" href="https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Lyfgenia/LYFGENIA_Prescribing_Information.pdf?v=20260608123731" rel="noopener noreferrer" style="font-family:IBMPlexSans-Bold; color:#00278F !important;" target="_blank">Prescribing Information</a>, including <span class="IBMPlexSans-Bold">Boxed WARNING</span> for LYFGENIA.</p>
1544    </div>
1545    <div class="col-lg-5 col-md-5 col-sm-12 pt-0 pt-md-3">
1546      <h2 class="mb-2 IBMPlexSans-Bold pt-0 pt-md-3" style="color:#218282; font-size:20px;">Indication</h2>
1547      
1548      <p>LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.</p><p class="mb-0"><span style="text-decoration: underline;">Limitations of Use</span></p><p>Following treatment with LYFGENIA, patients with <span class="text-nowrap">α-thalassemia</span> trait (-α3.7/-α3.7) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α-globin gene deletions.</p>
1549    </div>
1550  </div>
1551
1552  </div>
1553
1554  
1555  <div class="banner-content">
1556    <div class="container">
1557      
1558      <div class="banner-toolbar">
1559        <i class="banner-icon fas fa-2x fa-angle-down clickable"></i>
1560        <span class="banner-icon-collapse" style="display:none;"><i class="fas fa-2x fa-angle-down"></i></span>
1561        <span class="banner-icon-expand" style="display:none;"><i class="fas fa-2x fa-angle-up"></i></span>
1562      </div>
1563      
1564  <div class="row">
1565    <div class="col-lg-7 col-md-7 col-sm-12 pb-0 pb-lg-3 pt-3">
1566      <h2 class="IBMPlexSans-Bold mb-2 d-none d-md-block" style="color:#218282; font-size:20px;">Important Safety Information</h2>
1567      <h2 class="IBMPlexSans-Bold mb-2 d-block d-md-none expanded-hide" style="color:#218282; font-size:20px; padding-top:5px; margin-top:-15px; line-height: 1.2;">Important Safety<br> Information</h2>
1568      <h2 class="IBMPlexSans-Bold mb-2 d-block d-md-none expanded-show" style="color:#218282; font-size:20px; padding-top:5px; margin-top:-15px; line-height: 1.2;">Important Safety<br>Information and Indication</h2>
1569      
1570      <p class="IBMPlexSans-Bold mb-0 text-primary">Boxed WARNING: HEMATOLOGIC MALIGNANCY</p><p class="IBMPlexSans-Bold mb-2 text-black" style="line-height:22px;">Hematologic malignancy has occurred in patients treated with LYFGENIA. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through integration site analysis at Months 6, 12, and as warranted.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hematologic Malignancy</p><p class="mb-2" style="line-height:22px;">Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A). At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML). One patient with <span class="text-nowrap">α-thalassemia</span> trait (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS).</p><p class="mb-2" style="line-height:22px;">The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy. Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population.</p><p class="mb-2" style="line-height:22px;">Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.</p><p class="mb-2" style="line-height:22px;">In the event that a malignancy occurs, contact Genetix Biotherapeutics at 1-833-999-6378 for reporting and to obtain instructions on collection of samples for testing.</p><p class="mb-2" style="line-height:22px;"><span style="text-decoration: underline;">Post-Marketing Long Term Follow-Up Study:</span> Patients who intend to receive treatment with LYFGENIA are encouraged to enroll in the study, as available, to assess the long-term safety of LYFGENIA and the risk of malignancies occurring after treatment with LYFGENIA by calling Genetix Biotherapeutics at 1-833-999-6378. The study includes monitoring (at pre-specified intervals) for clonal expansion.</p>
1570<p class="IBMPlexSans-Bold mb-2 text-primary">Delayed Platelet Engraftment</p><p class="mb-2" style="line-height:22px;">Delayed platelet engraftment has been observed with LYFGENIA. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in patients with prolonged thrombocytopenia. Two patients (4%) required more than 100 days post treatment with LYFGENIA to achieve platelet engraftment.</p><p class="mb-2" style="line-height:22px;">Patients should be made aware of the risk of bleeding until platelet recovery has been achieved. Monitor patients for thrombocytopenia and bleeding according to standard guidelines. Conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved. Perform blood cell count determination and other appropriate testing whenever clinical symptoms suggestive of bleeding arise.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Neutrophil Engraftment Failure</p><p class="mb-2" style="line-height:22px;">There is a potential risk of neutrophil engraftment failure after treatment with LYFGENIA. Neutrophil engraftment failure is defined as failure to achieve three consecutive absolute neutrophil counts (ANC) ≥ 0.5 × 10<sup>9</sup> cells/L obtained on different days by Day 43 after infusion of LYFGENIA. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a patient treated with LYFGENIA, provide rescue treatment with the back-up collection of CD34+ cells.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Insertional Oncogenesis</p><p class="mb-2" style="line-height:22px;">There is a potential risk of lentiviral vector-mediated insertional oncogenesis after treatment with LYFGENIA.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hypersensitivity Reactions</p><p class="mb-2" style="line-height:22px;">Allergic reactions may occur with the infusion of LYFGENIA. The dimethyl sulfoxide (DMSO) or dextran 40 in LYFGENIA may cause hypersensitivity reactions, including anaphylaxis.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Anti-retroviral Use</p><p class="mb-2" style="line-height:22px;">Patients should not take prophylactic HIV anti-retroviral medications for at least one month prior to mobilization and until all cycles of apheresis are completed. There are some long-acting anti-retroviral medications that may require a longer duration of discontinuation for elimination of the medication. If a patient is taking anti-retrovirals for HIV prophylaxis, confirm a negative test for HIV before beginning mobilization and apheresis of CD34+ cells.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Hydroxyurea Use</p><p class="mb-2" style="line-height:22px;">Patients should not take hydroxyurea for at least 2 months prior to mobilization and until all cycles of apheresis are completed. If hydroxyurea is administered between mobilization and conditioning, discontinue 2 days prior to initiation of conditioning.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Iron Chelation</p><p class="mb-2" style="line-height:22px;">Drug-drug interactions between iron chelators and the mobilization process and myeloablative conditioning agent must be considered. Iron chelators should be discontinued at least 7 days prior to initiation of mobilization or conditioning. Do not administer myelosuppressive iron chelators (e.g., deferiprone) for 6 months post-treatment with LYFGENIA. Non-myelosuppressive iron chelation should be restarted no sooner than 3 months after LYFGENIA infusion. Phlebotomy can be used in lieu of iron chelation, when appropriate.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Interference with PCR-based Testing</p><p class="mb-2" style="line-height:22px;">Patients who have received LYFGENIA are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to integrated BB305 LVV proviral DNA, resulting in a possible false-positive PCR assay test result for HIV. Therefore, patients who have received LYFGENIA should not be screened for HIV infection using a PCR-based assay.</p>
1570<p class="IBMPlexSans-Bold mb-2 text-primary">Adverse Reactions</p><p class="mb-2" style="line-height:22px;">The most common adverse reactions ≥ Grade 3 (incidence ≥ 20%) were stomatitis, thrombocytopenia, neutropenia, febrile neutropenia, anemia, and leukopenia.</p><p class="mb-2" style="line-height:22px;">Three patients died during LYFGENIA clinical trials; one from sudden cardiac death due to underlying disease and two from acute myeloid leukemia who were treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A).</p><p class="IBMPlexSans-Bold mb-2 text-primary">Pregnancy/Lactation</p><p class="mb-2" style="line-height:22px;">Advise patients of the risks associated with myeloablative conditioning agents, including on pregnancy and fertility.</p><p class="mb-2" style="line-height:22px;">LYFGENIA should not be administered to women who are pregnant, and pregnancy after LYFGENIA infusion should be discussed with the treating physician.</p><p class="mb-2" style="line-height:22px;">LYFGENIA is not recommended for women who are breastfeeding, and breastfeeding after LYFGENIA infusion should be discussed with the treating physician.</p><p class="IBMPlexSans-Bold mb-2 text-primary">Females and Males of Reproductive Potential</p><p class="mb-2" style="line-height:22px;">A negative serum pregnancy test must be confirmed prior to the start of mobilization and re-confirmed prior to conditioning procedures and before LYFGENIA administration.</p><p class="mb-2" style="line-height:22px;">Women of childbearing potential and men capable of fathering a child should use an effective method of contraception (intra-uterine device or combination of hormonal and barrier contraception) from start of mobilization through at least 6 months after administration of LYFGENIA.</p><p class="mb-2" style="line-height:22px;">Advise patients of the options for fertility preservation.</p><p class="IBMPlexSans-Bold text-black">Please see full <a class="text-link text-primary Lato-Bold" href="https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate%20COM/Files/Lyfgenia/LYFGENIA_Prescribing_Information.pdf?v=20260608123731" rel="noopener noreferrer" style="font-family:IBMPlexSans-Bold; color:#00278F !important;" target="_blank">Prescribing Information</a>, including <span class="IBMPlexSans-Bold">Boxed WARNING</span> for LYFGENIA.</p>
1571    </div>
1572    <div class="col-lg-5 col-md-5 col-sm-12 pt-0 pt-md-3">
1573      <h2 class="mb-2 IBMPlexSans-Bold pt-0 pt-md-3" style="color:#218282; font-size:20px;">Indication</h2>
1574      
1575      <p>LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.</p><p class="mb-0"><span style="text-decoration: underline;">Limitations of Use</span></p><p>Following treatment with LYFGENIA, patients with <span class="text-nowrap">α-thalassemia</span> trait (-α3.7/-α3.7) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α-globin gene deletions.</p>
1576    </div>
1577  </div>
1578
1579    </div>
1580  </div>
1581
1582  <div class="banner-content-overlay"></div>
1583</div></div>
1584
1585        
1586        <div class="container-fluid">
1587<div class="row-fluid-wrapper">
1588<div class="row-fluid">
1589<div class="span12 widget-span widget-type-cell " style="" data-widget-type="cell" data-x="0" data-w="12">
1590
1591<div class="row-fluid-wrapper row-depth-1 row-number-1 dnd-section references-row-0-max-width-section-centering">
1592<div class="row-fluid ">
1593<div class="span12 widget-span widget-type-cell cell_17817626007183-padding dnd-column" style="" data-widget-type="cell" data-x="0" data-w="12">
1594
1595<div class="row-fluid-wrapper row-depth-1 row-number-2 dnd-row">
1596<div class="row-fluid ">
1597<div class="span12 widget-span widget-type-custom_widget dnd-module" style="" data-widget-type="custom_widget" data-x="0" data-w="12">
1598<div id="hs_cos_wrapper_widget_1781762256264" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625<div id="widget_1781762256264" class="cards">
1626  
1627  
1628  
1629  
1630  
1631  
1632  <div class="cards__card card-1">
1633
1634    
1635
1636    
1637
1638    <div class="cards__content">
1639
1640    
1641    
1642
1643    <div class="cards__copy"><div class="strip-component bg-white">
1644<div class="row">
1645<div class="col-md-12 pt-0">
1646<div class="text-black">
1647<p class="small IBMPlexSans-Bold mb-1">References</p>
1648<p class="small mb-2" style="position: relative; padding-left: 14px;"><span class="IBMPlexSans-Bold" style="position: absolute; left: -1px;">1.</span> Data on File, DOF-US-00061, Genetix Biotherapeutics Inc.; 2023.</p>
1649<p class="small mb-2" style="position: relative; padding-left: 14px;"><span class="IBMPlexSans-Bold" style="position: absolute; left: -1px;">2.</span> LYFGENIA [prescribing information], Somerville, MA; Genetix Biotherapeutics Inc.</p>
1650</div>
1651</div>
1652</div>
1653</div></div>
1654
1655    
1656
1657    </div>
1658
1659    
1660
1661    
1662
1663  </div>
1664  
1665  
1666</div>
1667</div>
1668
1669</div><!--end widget-span -->
1670</div><!--end row-->
1671</div><!--end row-wrapper -->
1672
1673</div><!--end widget-span -->
1674</div><!--end row-->
1675</div><!--end row-wrapper -->
1676
1677</div><!--end widget-span -->
1678</div>
1679</div>
1680</div>
1681
1682        <div id="hs_cos_wrapper_footer" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1683
1684
1685
1686
1687<div class="strip-component bg-primary common-footer py-4">
1688  <div class="grid-component container">
1689    <div class="row footer-primary-links pt-0 pb-1">
1690      <div class="col-md-12 pb-0 pt-2">
1691        <ul class="content-list">
1692          <li><a class="text-link" href="/faqs?hsLang=en">FAQs</a></li>
1693          <li><a class="text-link" href="/sitemap?hsLang=en">Site Map</a></li>
1694          <li><a class="text-link" href="https://www.genetixbiotx.com/privacy-policy?hsLang=en" rel="noopener noreferrer" target="_blank">Privacy Policy</a></li>
1695          <li><a class="text-link" href="https://www.genetixbiotx.com/terms-of-service?hsLang=en" rel="noopener noreferrer" target="_blank">Terms of Service</a></li>
1696          <li><a class="text-link" href="/cookie-notice/?hsLang=en" rel="noopener noreferrer" target="_self">Cookie Notice</a></li>
1697          <li><a class="text-link" href="/unsubscribe?hsLang=en">Unsubscribe</a></li>
1698        </ul>
1699      </div>
1700    </div>
1701  </div>
1702  <div class="grid-component container">
1703    <div class="row footer-text">
1704      <div class="col-md-10 col-12 pb-1 pt-1">
1705        
1706        
1707        <p>The information on this website is not intended to make a diagnosis or treatment recommendation or provide medical advice.</p>
1708<p>Genetix Biotherapeutics, the Genetix Biotherapeutics logo, LYFGENIA, and the LYFGENIA logo are trademarks of Genetix Biotherapeutics Inc.</p>
1709<p>© 2026 Genetix Biotherapeutics Inc. All rights reserved. LYF-US-00009-v4 08/26</p>
1710        
1711      </div>
1712      <div class="col-md-2 col-12 px-0 pb-0">
1713        <a href="https://www.bluebirdbio.com/" target="_blank">
1714          <img alt="Genetix Biotherapeutics logo" src="https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/logos/genetix-logo-white.svg" style="width: auto;">
1715        </a>
1716      </div>
1717    </div>
1718  </div>
1719</div></div>
1720
1721        <div id="hs_cos_wrapper_leaving_site_modal" class="hs_cos_wrapper hs_cos_wrapper_widget hs_cos_wrapper_type_module" style="" data-hs-cos-general-type="widget" data-hs-cos-type="module">
1722
1723
1724
1725
1726
1727
1728  <div class="modal modal-leaving-site fade" id="leaving-site" data-keyboard="true" role="dialog" tabindex="-1" aria-labelledby="leaving-site-title" aria-hidden="true" style="display: none;">
1729    <div class="modal-dialog modal-dialog-centered" role="document">
1730      <div class="modal-content">
1731
1732        
1733        <div class="modal-header">
1734          <h5 class="modal-title" id="leaving-site-title">
1735            
1736          </h5>
1737          
1738        </div>
1739
1740        
1741        <div class="modal-body">
1742          <div>
1743            <div class="col-sm-12">
1744
1745              
1746
1747              
1748              <h3 style="font-size: 26px;">You are about to leave LYFGENIAHCP.com.</h3>
1749        <p class="mb-3">This link will take you to a website that is outside the control of Genetix Biotherapeutics Inc. Links are provided for informational purposes only. We do not make or imply any endorsement of external websites.</p>
1750              
1751
1752              
1753              
1754              <div class="row">
1755                
1756                <div class="col-sm-12 pb-0 text-center">
1757                  <a class="ext-link-out btn btn-senary text-center px-3" style="border: 1px solid var(--color-primary);" href="#" rel="noopener noreferrer" target="_blank">Continue</a>
1758                </div>
1759                
1760                
1761                <div class="col-sm-12 pb-0 text-center">
1762                  <button type="button" class="btn btn-tertiary text-center py-3 px-2" data-dismiss="modal" data-bs-dismiss="modal" aria-label="Cancel">Cancel</button>
1763                </div>
1764                
1765              </div>
1766              
1767
1768            </div>
1769          </div>
1770        </div>
1771
1772      </div>
1773    </div>
1774  </div>
1775
1776
1777
1778<script>
1779(function() {
1780  var modalId = 'leaving-site';
1781  var modalEl = document.getElementById(modalId);
1782  if (!modalEl) return;
1783
1784  
1785
1786  // Stop any iframe playback (HubSpot video, YouTube, Vimeo, etc.) when the modal closes.
1787  modalEl.addEventListener('hidden.bs.modal', function() {
1788    modalEl.querySelectorAll('iframe').forEach(function(iframe) {
1789      var src = iframe.src;
1790      iframe.src = '';
1791      iframe.src = src;
1792    });
1793  });
1794})();
1795
1796if (typeof toggleModal === 'undefined') {
1797  function toggleModal(id) {
1798    if (typeof jQuery !== 'undefined') {
1799      var element = jQuery('#' + id);
1800      if (element.hasClass('show')) {
1801        element.modal('hide');
1802      } else {
1803        element.modal('show');
1804      }
1805    }
1806  }
1807}
1808</script>
1808</div>
1809      </footer>
1810
1811      
1812      <!-- Back To Top — verbatim copy of www.lyfgeniahcp.com markup.
1813     The "Back to Top" text is replaced by the icon SVG via `content` (theme.css).
1814     get_asset_url() supplies the SVG so HubSpot publishes it. -->
1815<style>
1816  #backToTop { content: url('https://www.lyfgeniahcp.com/hubfs/raw_assets/public/themes/lyfgeniahcp-theme/images/icon-back-to-top.svg'); }
1817</style>
1818<a href="#site-header" class="btn btn-quinary position-fixed" style="right:20px; bottom:5px;" id="backToTop">
1819  Back<br>to Top
1820</a>
1821<!-- Show/hide handled by js/back-to-top.js (#backToTop). -->
1822<!-- Back to Top End -->
1823
1824      
1825<!-- HubSpot performance collection script -->
1826<script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script>
vendor: 1 bytes, line 1826
1826
1827<script>
1828var hsVars = hsVars || {}; hsVars['language'] = 'en';
1829</script>
1829
1830
1831<script src="/hs/hsstatic/cos-i18n/static-1.53/bundles/project.js"></script>
1831
1832
1833  
1833<script data-hs-allowed="true">
1834    ((d=document,q='querySelectorAll',l='hs-form-html',m='script',b='/_hcms/forms/embed/v4/render-definition/ssr',u='https://js.hsforms.net/forms/embed/50895703.js') => {
1835      const a = (t,i) => t.replace(/{{hs_form_instance_id_placeholder}}/g,i);
1836      const i = (f,o) => {f.innerHTML=o;for(const s of f[q](m)){const n=d.createElement(m);for(const{name:e,value:t}of s.attributes)n.setAttribute(e,t);n.appendChild(d.createTextNode(s.innerHTML)),s.parentNode.replaceChild(n,s)}};
1837      const j = (e,f) => {const fb=()=>{const n=f.cloneNode(true);n.classList.replace(l,'hs-form-frame');i(f,'<'+m+' src="'+u+'"></'+m+'>'+n.outerHTML);};try{if(e.status === 404){e.text().then((t)=>{if(!/Form not found/i.test(t))fb();}).catch(fb);return;}}catch(_){}fb();};
1838      const r = (el,c=el.dataset) => {if(c.fetched)return;c.fetched=Date.now();fetch(`${b}/${c.portalId}/${c.formId}`).then((r) => {if(!r.ok)throw r;return r.text().then((t) => {i(el,a(t,el.id));c.loaded=Date.now();});}).catch((e) => j(e,el));};
1839      d[q]('.'+l).forEach((el) => r(el));
1840    })();
1841  </script>
1841
1842
1843
1844  
1844<script data-hs-allowed="true">
1845    ((el) => {
1846      el && el.addEventListener('hs-form-event:on-ready', (e) => {
1847      window.HubSpotFormsV4.getFormFromEvent(e).setExtraSubmissionMetadata({
1848        
1849        
1850        
1851        
1852        
1853        
1854        
1855      });
1856    });
1857    })(document.getElementById('hs_form_target_signup_signup'));
1858  </script>
1858
1859
1860<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195452426/1788288953958/template_ImportantInformationBanner.min.js"></script>
vendor: 1 bytes, line 1860
1860
1861<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195482482/1788288954866/template_back-to-top.min.js"></script>
vendor: 1 bytes, line 1861
1861
1862<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213194501277/1789504228223/template_navigation.min.js"></script>
vendor: 1 bytes, line 1862
1862
1863<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/219488405848/1788288957557/template_modal-trigger.min.js"></script>
vendor: 1 bytes, line 1863
1863
1864<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195452430/1788288953870/template_smooth-scroll.min.js"></script>
vendor: 1 bytes, line 1864
1864
1865<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/213195482508/1788288954839/template_form-handler.min.js"></script>
vendor: 1 bytes, line 1865
1865
1866<script src="https://www.lyfgeniahcp.com/hubfs/hub_generated/template_assets/1/216059520154/1788288956420/template_chart-scroll.min.js"></script>
1866
1867
1868<!-- Start of HubSpot Analytics Code -->
1869<script type="text/javascript">
1870var _hsq = _hsq || [];
1871_hsq.push(["setContentType", "standard-page"]);
1872_hsq.push(["setCanonicalUrl", "https:\/\/www.lyfgeniahcp.com"]);
1873_hsq.push(["setPageId", "214210248272"]);
1874_hsq.push(["setContentMetadata", {
1875    "contentPageId": 214210248272,
1876    "legacyPageId": "214210248272",
1877    "contentFolderId": null,
1878    "contentGroupId": null,
1879    "abTestId": null,
1880    "languageVariantId": 214210248272,
1881    "languageCode": "en",
1882    
1883    
1884}]);
1885</script>
1885
1886
1887<script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/50895703.js"></script>
1887
1888<!-- End of HubSpot Analytics Code -->
1889
1890
1891<script type="text/javascript">
1892var hsVars = {
1893    render_id: "2e4747cb-c1c9-4997-aa78-9ba6beee23c8",
1894    ticks: 1790953982296,
1895    page_id: 214210248272,
1896    
1897    content_group_id: 0,
1898    portal_id: 50895703,
1899    app_hs_base_url: "https://app.hubspot.com",
1900    cp_hs_base_url: "https://cp.hubspot.com",
1901    language: "en",
1902    analytics_page_type: "standard-page",
1903    scp_content_type: "",
1904    
1905    analytics_page_id: "214210248272",
1906    category_id: 1,
1907    folder_id: 0,
1908    is_hubspot_user: false
1909}
1910</script>
1910
1911
1912
1913<script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.640/js/index.js"></script>
1913
1914
1915
1916
1917
1918      
1918<script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
1918
1919      
1919<script src="https://cdn.jsdelivr.net/npm/[email protected]/dist/js/bootstrap.bundle.min.js"></script>
1919
1920      
1920<script src="https://unpkg.com/@popperjs/core@2/dist/umd/popper.min.js"></script>
1920
1921      
1921<script src="https://unpkg.com/tippy.js@6/dist/tippy.umd.min.js"></script>
1921
1922      
1922<script>
1923        document.addEventListener('DOMContentLoaded', function() {
1924          tippy('.term-dialog-button[data-template]', {
1925            content: function(el) {
1926              var id = el.getAttribute('data-template');
1927              var tpl = document.getElementById(id);
1928              return tpl ? tpl.innerHTML : '';
1929            },
1930            allowHTML: true,
1931            theme: 'lyf-glossary',
1932            arrow: true,
1933            trigger: 'mouseenter click',
1934            interactive: true,
1935            hideOnClick: false,
1936            delay: [100, 300],
1937            placement: 'top',
1938            appendTo: function() { return document.body; },
1939            onMount: function(instance) {
1940              instance.reference.setAttribute('aria-expanded', 'true');
1941              var closeBtn = instance.popper.querySelector('.close');
1942              if (closeBtn) {
1943                closeBtn.addEventListener('click', function() { instance.hide(); });
1944              }
1945            },
1946            onHide: function(instance) {
1947              instance.reference.setAttribute('aria-expanded', 'false');
1948            }
1949          });
1950        });
1951      </script>
1951
1952
1953      
1954      
1955      
1956      
1957      
1958      
1959      
1960
1961
1962
1963</body></html>

Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.